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Abstract
Thyroid carcinoma is the most prevalent endocrine malignancy and accounts for 2% of
all human cancers. In the past decade, knowledge of genetic alterations of thyroid cancer
(TC)  has  rapidly  expanded,  which has  provided new insights  into  thyroid cancer
etiology and has offered novel diagnostic tools and prognostic markers that enable
improved and personalized management of thyroid cancer patients. Alterations in key
signaling effectors seem to be the hallmark of  distinct  forms of  thyroid neoplasia.
Mutations or rearrangements in genes that encode Mitogen activated protein kinase
(MAPK) pathway effectors seem to be required for transformation. Mutations in BRAF
were the most recently identified MAPK effector in thyroid cancer. BRAF V600E is the
most common alteration in sporadic papillary carcinoma. Three RAS proto-oncogenes
(NRAS, HRAS & KRAS) are implicated in human thyroid tumorigenesis. High incidence
of thyroid cancer worldwide indicates the importance of studying genetic alterations
that lead to its carcinogenesis. BRAF and RAS alterations represent a novel indicator of
the  progression  and  aggressiveness  of  thyroid  carcinogenesis.  The  GSα-adenylyl
cyclase-cyclic AMP (cAMP) cascade is effected in thyroid cancer. Promoter hyperme‐
thylation of multiple genes especially TSHR has been identified to play a role in thyroid
cancers, in particular showing a close association with BRAF mutational status. So, the
main aim of  the  study was  to  elucidate  the  involvement  of  BRAF  and RAS  gene
mutations  along with BRAF expression and thyroid-stimulating hormone receptor
(TSHR) hypermethylation in North Indian patients and investigate their association
with clinicopathological characteristics.
We screened exon 15 of BRAF gene and exons 1 and 2 of RAS genes (HRAS, KRAS, and
NRAS) in 60 consecutive thyroid tissue (tumor and adjacent normal) samples. Overall
mutations in BRAF were found to be 25% (15 of 60) affecting codon 600 (valine to
glutamine) and restricted only to papillary thyroid cancer and well-differentiated grade.
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BRAF mutations were significantly associated with well-differentiated disease and
elevated thyroid-stimulating hormone (TSH) levels (P < 0.05). Overall, increased
expression of BRAF was found in 90% (54 of 60) of thyroid cancer cases and signifi‐
cantly associated with nonsmokers. Totally, 86.7% (13 of 15) of BRAF mutation-
positive patients were having BRAF protein overexpression compared to 91.2% (41 of
45) of patients with wild-type BRAF status (P > 0.05). We screened 60 consecutive thyroid
tumor and adjacent normal tissues for mutations, if any, in the exons 1 and 2 of RAS
genes (HRAS, KRAS, and NRAS) and 140 blood samples from thyroid cancer patients
for HRAS T81C polymorphism in codon 27 in comparison with 170 cancer-free controls
from a Kashmiri population. Thyroid tumor tissue samples were devoid of any
mutation, but a frequent nucleotide change at position 81 (T > C) in exon 1 of HRAS
gene was seen. In HRAS T81C SNP, frequencies of TT, TC, and CC genotypes among
cases were 41.4, 38.6, and 20.0%, while in controls genotype frequencies were 84.1, 11.7,
and 4.2%, respectively. A significant difference was observed in variant allele frequen‐
cies (TC + CC) between the cases and controls (58.6 vs. 16%) with odds ratio of 7.4 (CI
= 04.3–12.7; P < 0.05). Interestingly, combined TC and CC genotype abundantly
presented in follicular thyroid tumor (P < 0.05). Moreover, a significant association of
the variant allele (TC + CC) was found with nonsmokers (P < 0.05). TSHR gene was
found to be hypermethylated in 25% (15 of 60) of the cases with strong association with
elevated TSH levels (OR = 4.0, P = 0.02). TSHR promoter was hypermethylated in 73.3%
(11 of 15) of patients with BRAF V600E mutation compared to 26.7% (4 of 15) of patients
having absence of TSHR promoter methylation and the association was significant (P <
0.05).
We conclude that both mutational events and overexpression of BRAF gene are highly
implicated in pathogenesis of thyroid cancer and the BRAF protein overexpression is
independent of the BRAF mutational status of thyroid cancer patients. RAS gene
mutation does not prevail in this population. Contrary to this, HRAS T81C polymor‐
phism moderately increases thyroid cancer risk with rare allele as a predictive marker
for follicular tumors. Our study showed a high implication of TSHR gene methylation
and its significant association with BRAF V600E mutation in thyroid tumors, depict‐
ing a positive connection between TSHR pathway and MAP kinase pathway.
Keywords: polymerase chain reaction, papillary thyroid cancer, thyroid-stimulating
hormone, benign thyroid disease, lymph node metastasis, follicular thyroid cancer,
mutation, polymorphism, gene, hypermethylation, genotype, expression
1. Introduction
Thyroid gland is the largest endocrine gland comprised of follicular cells and C cells. It
synthesizes, stores, and secretes triiodothyronine (T3) and thyroxine (T4) (Figure 1). Follicular
cells comprise most of the epithelium and are responsible for iodine uptake and thyroid
hormone synthesis. C cells are dedicated to the production of the calcium-regulating hormone
calcitonin [1].
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Figure 1. The thyroid gland.
At molecular level, cancer is caused by molecular defects in cell function resulting from
common types of alterations to a cell’s genes. Cancer is a disease of abnormal gene expression
which may occur due to DNA mutation, translocation, amplification, deletion, loss of hetero‐
zygosity, etc. The overall result is an imbalance of cell replication and cell death that leads to
unregulated growth and spread of cells in different parts of body [2, 3].
Thyroid cancer (TC) typically occurs in thyroid nodules and is relatively common, occurring in
6% of adult women and 2% of adult men which can be detected by palpation and imaging in
a large proportion of adults. Approximately 90% of thyroid malignancies are well-differenti‐
ated thyroid carcinomas arising from thyroid follicular epithelial cells, which are classified as
papillary or follicular based on histopathological criteria, whereas 3–5% of cancers originate
from parafollicular or C cells. Follicular adenoma is a benign tumor that may serve as a
precursor for some follicular carcinomas. Recurrence occurs in 20–40% of patients in spite of
the fact that differentiated thyroid carcinomas are usually curable by the combination of
surgery, radioiodine ablation, and thyroid-stimulating hormone suppressive therapy [4] due
to cellular dedifferentiation which is accompanied by more aggressive growth, metastatic
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spread, and loss of iodide uptake ability, making the tumor resistant to the traditional
therapeutic modalities and radioiodine [5]. Knowledge of genetic alterations occurring in
thyroid cancer has rapidly expanded in the past decade. This improved knowledge has
provided new insights into thyroid cancer etiology and has offered novel diagnostic tools and
prognostic markers that enable improved and personalized management of patients with
thyroid nodules [6].
TC is the most common malignancy of the endocrine system. It accounts for approximately
2% of all newly diagnosed cancer cases and majority of endocrine cancer related deaths each
year [7, 8]. An estimated 12.66 million people were diagnosed with cancer across the world in
2008, and 7.56 million people died from the disease. This equates to around 188 cases for every
100,000 people (using the crude rate). Among the 20 most commonly diagnosed cancers
worldwide, thyroid cancer figures on 17th (2% of all cancers) number (2008 estimates) [9].
There were 213,179 new thyroid cancer cases and 163,000 cases among females worldwide by
the year 2008 [10]. Its prevalence continues to rise; in 2008, it became the sixth most diagnosed
cancer among women in United States Around 56,460 cases (men – 13,250, women – 43,210)
and 1780 deaths (men – 780, women – 1000) from thyroid cancer occurred in 2012 [11]. The
data indicated that there were 60,220 new cases in 2013, accounting for 3.6% of all new cancer
cases. There were 1850 thyroid cancer-related deaths in 2013, accounting for 0.3% of all cancer
deaths. There are currently ~534,973 TC patients in USA. The reasons for increased incidence
are unclear, with potential explanations including increased screening, more widespread
diagnostic testing of asymptomatic thyroid nodules, changing demographics, and environ‐
mental risk factor. TC accounts for approximately 10% of malignancies diagnosed in persons
aged 15–29 years. Follicular cancers include papillary thyroid cancer (PTC, 80%), follicular
thyroid cancer (FTC, up to 11%), Hürthle cell cancer (3%), and anaplastic thyroid cancer (ATC,
2%). Medullary thyroid cancer (MTC) accounts for about 4% of thyroid cancers [12]. As
expected from the size of Asia’s population, the majority of cancer cases occurred there.
Between 1984 and 1993, over 5614 thyroid cancer cases were recorded in India which included
2007 males and 3617 females and the age standardized rate (ASR) in 1993 was 1.0/year/105 and
1.9/year/105 for males and females, respectively [13]. The age-adjusted incidence rates of
thyroid cancer per 100,000 are about 1 for males and 1.8 for females as per the Mumbai Cancer
Registry, which covered a population of 9.81 million subjects. The commonest cancer type was
papillary, followed by follicular cancer. TC is the 8th most common cancer in the valley of
Kashmir and 7th most common cancer among women of Kashmir valley. Among all types of
cancers in the Kashmir valley, the frequency of TC has increased from 2.3% in 1995 to 5.4% in
2010, keeping overall frequency of 3.2% [14].
2. Classification of thyroid tumors
The classification of thyroid tumors is given by the World Health Organization (WHO) and
Armed Forces Institute of Pathology (AFIP) with slight difference [15]. According to AFIP,
priority is given to the cell of origin and incorporating, in each cell type, special tumor types
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and subtypes designated as “variants”. Classification scheme adopted by the Armed Forces
Institute of Pathology (AFIP) is depicted in Figure 2.
Figure 2. Classification of thyroid tumors as per Armed Forces Institute of Pathology (AFIP).
3. Staging of thyroid carcinoma
There are different stages of TC as designated by the American Joint Committee on Cancer
(AJCC) [15]. The SEER modified 7th edition AJCC staging is given in Tables 1 and 2.




TX  Primary tumor cannot be assessed
T0  No evidence of primary tumor is found
T1  Tumor size ≤ 2 cm in greatest dimension and is limited to the thyroid
T1a  Tumor ≤ 1 cm, limited to the thyroid
T1b  Tumor > 1 cm but ≤ 2 cm in greatest dimension, limited to the thyroid
T2  Tumor size > 2 cm but ≤ 4 cm, limited to the thyroid
T3  Tumor size > 4 cm, limited to the thyroid or any tumor with minimal extrathyroidal extension (e.g., extension to
sternothyroid muscle or perithyroid soft tissues)
T4a  Moderately advanced disease; tumor of any size extending beyond the thyroid capsule to invade subcutaneous
soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve
T4b  Very advanced disease; tumor invades prevertebral fascia or encases carotid artery or mediastinal vessel
All anaplastic carcinomas are considered stage IV:
T4a  Intrathyroidal anaplastic carcinoma
T4b  Anaplastic carcinoma with gross extrathyroid extension
Regional lymph nodes (N)
Regional lymph nodes are the central compartment, lateral cervical, and upper mediastinal lymph nodes:
NX  Regional nodes cannot be assessed
N0  No regional lymph node metastasis
N1  Regional lymph node metastasis
N1a Metastases to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)
N1b Metastases to unilateral, bilateral, or contralateral cervical (levels I, II, III, IV, or V) or retropharyngeal or
superior mediastinal lymph nodes (level VII)
Distant metastasis (M) 
M0  No distant metastasis is found
M1  Distant metastasis is present
Table 1. TNM classification for thyroid cancer (SEER modified 7th edition AJCC staging).
Stage grouping
Separate stage groupings are recommended for papillary or follicular (differentiated), medullary, and anaplastic
(undifferentiated) carcinoma
Papillary and follicular thyroid cancer (age < 45y):
Stage T N M
I Any T Any N M0
II Any T Any N M1
Papillary and follicular; differentiated (age ≥ 45y):
Stage T N M
I T1 N0 M0
II T2 N0 M0
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Stage grouping
Separate stage groupings are recommended for papillary or follicular (differentiated), medullary, and anaplastic
(undifferentiated) carcinoma
III T3 N0 M0
IVA T1-3 N1a M0
T4a N1b M0
IVB T4b Any N M0
IVC Any T Any N M1
Anaplastic carcinoma (all anaplastic carcinomas are considered stage IV):
Stage T N M
IVA T4a Any N M0
IVB T4b Any N M0
IVC Any T Any N M1
Medullary carcinoma (all age groups):
Stage T N M
I T1 N0 M0
II T2, T3 N0 M0
III T1–T3 N1a M0






T4a N0, N1b M0
T1-T4a N1b M0
IVB T4b Any N M0
IVC Any T Any N M1
Table 2. Stage grouping of thyroid cancer (SEER modified 7th edition AJCC staging).
4. Risk factors of thyroid cancer
4.1. Gender and age
Females exhibit a better prognosis than men. TC is 2–4 times more frequent in women. It is
rare in patients aged <16 years, presenting an annual incidence of 0.02–0.3/100.000 [16, 17].
Its incidence increases with ageing, and the average age at diagnosis is 45–50 years.




TC incidence has a geographic and ethnic variability. The incidence of TC in areas such as
Iceland, Hawaii, the Philippines, Japan, and Israel is higher than in North America, Canada,
and US. In US, the TC is more frequent in Caucasian descent subjects. All these findings suggest
that such differences may be attributable to both environmental (e.g., dietary habits) and
genetic factors [18].
4.3. Previous exposure to ionizing radiation
Previous exposure to ionizing radiation for external irradiation of the neck increases the
incidence of thyroid nodules, either benign or malignant. Palpable nodules are detected in
20–30% of people exposed to radiation and in pediatric patients undergoing radiation ther‐
apy for oncological and hematological malignancies such as lymphoma or leukemia [19,
20].
4.4. Age at the time of irradiation
Irradiation is no longer an increased risk after 15–20 years of age. In children exposed to
doses of 1 Gy, the excess risk for TC is equal to 7.7 [21]. Several studies have shown an
increased risk of TC in children aged between 5 months and 10 years after the Chernobyl
nuclear disaster [22].
4.5. Previous history of benign thyroid disease (BTD)
People with benign thyroid conditions like an enlarged thyroid (goiter), thyroid nodules
(adenomas), and inflammation of the thyroid (thyroiditis) are more likely to develop thyroid
cancer. Approximately 1 in 5 thyroid cancers (20%) occur in people who have had a BTD in
the past [23].
4.6. Contribution of iodine in the food
In areas of sufficient iodine intake, PTC is more prevalent (80% of TCs), whereas in iodine-
deficient areas, FTCs and ATCs are 2–3 times more frequently reported as compared to areas
with adequate iodine intake [24].
4.7. Body mass index
High body mass index (BMI) has been shown as a risk factor for TC according to several case-
control studies. There is a fivefold risk in obese men and 2 times in obese women. In postme‐
nopausal women, weight gain of >14% positively correlates with the onset of TC [25].
4.8. Hormonal factors
According to the period of life in which thyroid cancer occurs, the female:male incidence ratio
is different. In women of child bearing age, this ratio is about 4:1 and 1.5:1 in older, prepuberal,
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and menopause individuals [26]. TSH regulates the growth and function of the thyroid gland
[27]. Growth of some thyroid cancers is dependent on TSH secretion and suppression of TSH
release by administration of thyroxin is often an effective treatment for thyroid carcinomas.
The thyroxine-binding globulin level in normal females is 10–20% higher than in males and in
pregnancy, a 50% increase in the level of thyroxine-binding globulin results in a similar
magnitude increase in TSH level [28]. It therefore appears likely that TSH levels of non
pregnant normal females will be elevated above the level in males at some point in the
menstrual cycle although not necessarily throughout the cycle. An elevated risk was also
reported in women who used estrogens for gynecological problems. In some studies, higher
levels of estrogen receptors (ERs) were found in neoplastic than in normal thyroid tissues [29].
The ligand-bound dimer ER can interact with an estrogen-responsive element, resulting in
transcriptional activation of the target gene [30]. 17 β-estradiol stimulates cell cycle progression
early in G1 phase by induction of cyclin D1 gene expression. In different cell lines, the induction
of cell growth was found to correlate with increased expression of cyclin D1 protein levels [31].
4.9. Smoking status
Although relatively little is known about the etiology of thyroid cancer beyond its association
with radiation exposure and some previous thyroid disorders [32], data are slowly accumu‐
lating as to the protective effect of cigarette smoking on this disease. Thyroid cancer has been
negatively associated with cigarette smoking in a number of studies, possibly consistent with
the greater occurrence of the disease in women than in men [33]. There are at least five distinct
proposed mechanisms for the effect of tobacco smoke on thyroid function. The first one relates
to a smoking-related reduction in TSH secretion, as it has long been hypothesized that elevated
levels of TSH may increase the risk of thyroid cancer. The lower body weight among smokers
compared to nonsmokers is a second proposed explanation, as increased body weight was
associated with a slightly increased thyroid cancer risk in the above-mentioned pooled
analysis. A third possible biological pathway lies in the potential anti-estrogenic effect of
cigarette smoke; a role for estrogen in the etiology of thyroid cancer is hypothesized because
of the higher incidence of this cancer in females relative to males [34]. The fourth is higher levels
of thyroxine-binding globulin and testosterone among smokers compared to nonsmokers and
the fifth is the higher levels of thyrotoxins in tobacco smoke in heavy smokers compared to
light and moderate smokers [35].
4.10. Oxidative stress
Oxidative stress (OS) is a state of excessive free radicals and reactive metabolites. In es‐
sence, OS represents an imbalance between the production of oxidants and their elimina‐
tion by anti oxidative systems in the body. Many studies have linked OS to thyroid cancer
by showing its association with abnormally regulated oxidative or antioxidative molecules
[36].
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5. Molecular biology of thyroid cancer
Thyroid tumors represent an appropriate model for the study of epithelial neoplastic trans‐
formation. The roles of somatic mutations, gene rearrangement (s), and level of gene expression
in carcinogenesis are now well established. The application of molecular techniques to thyroid
tumors has focused particular attention on the role of point mutations activating (or inhibiting)
the genes for the TSH receptor (TSHR), RAS, BRAF, Gsp, P53, etc, specific rearrangements of
the oncogenes RET and TRK and alterations in the pattern of expression of the oncogene BRAF,
MET, etc [37]. The theory of sequential progression of well-differentiated thyroid carcinoma
to poorly differentiated and undifferentiated thyroid carcinoma is because of genetic imbal‐
ances [38]. Figure 3 depicts the model of multi-step carcinogenesis of thyroid neoplasms.
Figure 3. Model of multi-step carcinogenesis of thyroid neoplasms. The proposed model of thyroid carcinogenesis is
based on general concepts and specific pathways. (a) Risk factors, such as exposure to radiation, induce genomic insta‐
bility through direct and indirect mechanisms, resulting in early genetic alterations. (b) Scheme of step-wise dediffer‐
entiation of follicular cell-derived thyroid cancer along with genetic alterations.
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Biomarkers, also known as molecular markers, biological markers, or tumor markers have become
useful not only for detecting thyroid cancer early, but also for detecting recurrent and
persistent disease and for predicting the effectiveness of surgical removal, radioiodine
ablation, and chemotherapy since the past 40 years, and they include genetic mutations and
molecular changes. Nowadays, high-throughput genomic and proteomic assays are being
used to identify a multitude of biomarker signature for each tumor type at any given stage [39,
40]. These biomarkers are discussed in detail as under.
5.1. Serum-based biomarkers
Serum biomarkers represent the first generation of thyroid biomarkers. Ideally, a serum
biomarker is one that is highly sensitive and specific, can establish diagnostic certainty and
can be easily measured.
5.1.1. Calcitonin
Para follicular C cells secrete calcitonin, which is a serum-based marker for MTC [41]. Overall,
calcitonin is more sensitive for documenting recurrent tumor but CEA levels are better
predictors of tumor aggressiveness. RET mutations have replaced calcitonin to a greater
because it is more sensitive and specific [42].
5.1.2. Thyroglobulin
Tg is a valuable serum marker for detecting recurrent or persistent well-differentiated thyroid
cancer of follicular cell origin, as there should be no Tg present after a total thyroidectomy
unless residual thyroid tissue is present. More recently, molecular studies using reverse
transcriptase-polymerase chain reaction (RT-PCR) have been used to measure tissue-tumor-
specific messenger RNA levels of Tg in the circulation [43].
5.2. Mutation-based biomarkers
Genetic alterations in thyroid tumors can be divided into two categories: inheritable (germline)
mutations and sporadic (somatic) mutations. Investigations into the inheritable and sporadic
mutations in thyroid cancer have proceeded in parallel with one another. The single known
inheritable gene mutation associated with thyroid cancer is a point mutation in the RET proto-
oncogene that causes medullary thyroid cancer [44]. The first sporadic mutation identified in
thyroid cancer was described in 1987 and involved a genetic defect in the RAS protein family
[45] followed by somatic RET/PTC translocations in 1990 and P53/NTRK1 mutations in 1992.
In the year 2000, PAX8/PPARgamma translocations were found in follicular thyroid cancers
[46] followed by the discovery of BRAF mutations, first in melanoma, then in PTC in 2003 [47].
The mutation-based biomarkers are discussed below in detail.
5.2.1. Chromosomal rearrangements
RET/PTC is a chromosomal rearrangement found in PTC. These chimeric genes contain the
portion of RET encoding intact tyrosine kinase domain fused to an active promoter of another
Molecular Alterations and Expression Dynamics in the Etiopathogenesis of Thyroid Cancer
http://dx.doi.org/10.5772/63740
25
gene that drives the expression and ligand-independent dimerization of the RET/PTC protein,
leading tumorigenesis in thyroid cells [48]. RET/PTC1 and RET/PTC3 are the most common
rearrangement types in which RET is fused to either CCDC6 (also known as H4) or NCOA4
(also known as ELE1 or RFG), respectively [49]. Both of these rearrangement types are
paracentric, intrachromosomal inversions. RET/PTC2 and nine more recently discovered types
of RET/PTC rearrangements are all interchromosomal rearrangements formed by RET fusion
to genes located on different chromosomes [50]. RET/PTC rearrangement occurs in 10–20% of
PTC. Thyroid adenomas and other benign nodules and nonneoplastic thyroid lesions have 10–
45% of RET/PTC rearrangements [51]. Chromosomal rearrangements involving another
receptor tyrosine kinase gene, NTRK1 have been reported to occur in up to 10–15% of PTC in
some series of patients although the prevalence of this rearrangement in papillary carcinomas
from many geographical areas is probably <2–5% [52]. PAX8/PPARγ rearrangement leads to
the fusion between a portion of the paired-box gene 8 gene (PAX8) and peroxisome prolifer‐
ator-activated receptor gamma gene (PPARγ). The fusion oncoprotein contributes to malig‐
nant transformation by targeting several cellular pathways. The PPARγ rearrangements are
found in follicular thyroid adenomas (0–31%) and follicular thyroid carcinomas (25–63%) [53].
5.2.2. RET point mutations (familial medullary thyroid cancer)
The RET gene encodes the RET receptor expressed in neuroendocrine and neural cells.
The nucleotide sequence of the RET gene was determined and in 1989 and was mapped to
chromosome 10q11.2 [54, 55]. In 1993, the specific germline mutations of the RET gene
were found to develop MTC [56]. Point mutations of the RET gene that causes MTC result
in a gain of function of the RET receptor. The hereditary RET point mutations are the
most specific biomarkers in clinical use today for diagnosing patients who will develop
MTC. No other currently used thyroid cancer biomarker is as sensitive or specific.
5.2.3. RAS mutations
The beginning of RAS research can be traced back to 1964 when Jennifer Harvey observed that
a preparation of a murine leukemia virus, taken from a leukemic rat, induced sarcomas in new-
born rodents [57]. The nucleotide sequences of the v-h-ras and v-k-ras oncogenes were not
published until the autumn of 1982, a time when the excitement in the RAS field was shifting
towards the recently isolated human oncogenes. By 1983, a new human transforming gene
was identified and found to be a third member of the RAS gene family. This gene was
designated NRAS [58]
5.2.3.1. RAS signaling
RAS proteins are signal switch molecules that regulate cell fates by coupling receptor acti‐
vation to downstream effector pathways that control diverse cellular responses including
proliferation, differentiation, and survival [59]. Human cancers frequently express mutant
RAS proteins, termed ‘oncogenic RAS’. RAS proteins are GDP/GTP binding proteins that
functions as a molecular switches to mediate downstream signaling from a variety of ex‐
tracellular stimuli. The RAS proteins are activated when the protein binds GTP and be‐
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comes inactive upon GTP hydrolysis to GDP by RAS proteins. The action of RAS proteins
is regulated by several guanine-nucleotide exchange factor (GNEFs) and GTPase-activating
proteins (GAPS). RAS proteins regulate cellular responses to many extracellular stimuli,
including soluble growth factors. GTP-bound RAS can interact productively with more
than 20 effectors, including Raf, phosphatidylinositol 3-kinase (PI3K) and Ral guanine nu‐
cleotide-dissociation stimulator (RALGDS), to regulate various cellular responses including
proliferation, survival, and differentiation [60]. RAS–GTP also binds the catalytic subunit of
type I PI3Ks causing translocation of PI3K to the plasma membrane and subsequent activa‐
tion. PI3K phosphorylates phosphatidyl inositol-4,5-bisphosphate (PIP2) to generate phos‐
phatidylinositol-3,4, 5-triphosphate, which activates downstream kinases such as Akt [61]
(Figure 4).
Figure 4. Overview of known RAS effectors and their corresponding biological responses. Active RAS-GTP induces a
wide variety of cellular processes, such as transcription, translation, cell-cycle progression, apoptosis or cell survival,
through direct interaction with various effectors. GAP proteins also interact with RAS-GTP and might also act as effec‐
tors. Modulators of some of these pathways are also indicated. The blue boxes represent adaptor complexes.
5.2.3.2. Oncogenic RAS mutations and abnormal signaling
Somatic missense RAS mutations found in cancer cells involve amino acid substitutions at
positions 12, 13, and 61 impairing the intrinsic GTPase activity and conferring resistance to
GAPs, thereby causing active, GTP-bound conformation to accumulate [62]. Glutamine 61 is
essential for GTP hydrolysis, and substituting any amino acid at this position except glutamic
acid blocks hydrolysis. Replacing glycine 12 of RAS with any other amino acid except proline
also biochemically activates RAS. Substituting proline for glycine 12 renders RAS resistant to
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GAPs but has increased intrinsic GTP hydrolysis. Consistent with this idea, the transforming
potential of HRAS proteins with different codon 61 substitutions is inversely related to intrinsic
GTPase activities [63]. Oncogenic RAS proteins deregulate downstream effector pathways to
confer the abnormal functional properties of cancer cells: deregulated cell growth, survival,
and differentiation.
5.2.3.3. Role of oncogenic RAS gene in thyroid cancer
Activating RAS mutations occur in ~30% of human cancers. Activated oncogenes of the RAS
family have been identified in a wide range of solid and hematological malignancies. Muta‐
tions that cause activation of the RAS proto-oncogene have been well defined, and several
groups have studied the occurrence of different mutations in thyroid neoplasia. The RAS
mutations generally occur in up to 20–50% of thyroid neoplasms. However, the prevalence of
mutations in specific histological classes varies widely. In papillary carcinomas, RAS muta‐
tions are relatively infrequent, as they occur in 10–20% of tumors. In FTC, RAS mutations are
found in 40–50% of tumors and may also correlate with tumor dedifferentiation and less
favorable prognosis [64]. RAS mutations are found in 20–40% of poorly differentiated and
anaplastic carcinomas, 20–40% of benign follicular adenomas [65]. RAS mutations may
predispose well-differentiated cancers to de differentiation and anaplastic transformation.
Because RAS mutations are found in the entire spectrum of thyroid cancers, and with increas‐
ing frequency as tumors become more undifferentiated, RAS mutations have been suggested
to be a biomarker for a more aggressive form of thyroid cancer [64]. In Thyroid cancer, NRAS
codon 61 and HRAS codon 61 mutations are most common.
5.2.4. BRAF mutations
Point mutations, small in-frame deletions/insertions, and/or chromosomal rearrangement are
the events by which BRAF can be activated. The most common BRAF activation is due to a
point mutation involving substitution of thymine by adenine at nucleotide position 1799,
resulting in a valine-to-glutamate replacement at residue 600 [66]. This BRAF V600E mutation
constitutes 98–99% of all BRAF mutations found in thyroid cancer. Lys601Glu point mutation
and small, in-frame insertions or deletions and AKAP9/BRAF rearrangement are other
alterations in BRAF [67]. The BRAF V600E mutation is found in 40–45% PTCs. The mutation
also occurs in 20–40% of poorly differentiated thyroid carcinomas and 30–40% of ATCs [68].
ARAF, BRAF, and CRAF are three RAF paralogs. These are downstream molecules of the
membrane-bound RAS [69]. RAS stimulates RAF activation, which in turn activates MEK
and ERK. ERK regulates cell proliferation, differentiation, senescence, and apoptosis. This
pathway is hyper-activated in 30% of cancers with activating mutations in RAS occurring
in approximately 15–30% of cancers, and recent data have shown that BRAF is mutated in
about 7% of cancers [70], identifying it as another important oncogene on this pathway.
The BRAF gene is located on the long (q) arm of chromosome 7 at position 34. More pre‐
cisely, the BRAF gene is located from base pair 140,433,811 to base pair 140,624,563 on
chromosome 7.
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5.2.4.1. BRAF mutations from A to Z
BRAF mutations are found in 27–70% of malignant melanomas, 36–53% of PTC, 5–22% of
colorectal cancers, and <30% of serous ovarian cancer, but they also occur at a low frequency
of 1–3% in a wide variety of other cancers [70, 71]. There are more than 40 mutations identified
in the BRAF gene so far, among which BRAF V600E mutation accounts for more than 90% [72,
73]. A few other activated BRAF mutants are only rarely found in thyroid cancer, such as the
BRAF K601E, AKAP9-BRAF [74], BRAF V599ins [75], K601del, and a recently characterized
novel BRAF mutant, V600D, FGLAT 601–605ins, resulting from an insertion of 18 nucleotides
at nucleotide T1799 of the BRAF gene [76].
5.2.4.2. BRAF mutation in thyroid cancer
Although there are lots of alterations in BRAF gene in thyroid cancer, the most important
mutation found in TC is BRAF V600E. This mutation is exclusive to PTC and PTC-derived ATC
(44% and 24%, respectively), as it does not occur in any other type of TC.
5.2.4.2.1. Association of BRAF mutation with high-risk clinicopathological characteristics of PTC
Many studies have investigated the relationship of BRAF mutation with clinicopathological
characteristics of PTC. Although the results are not entirely consistent, most of the studies from
various ethnic and geographical backgrounds demonstrate a significant association of BRAF
mutation with one or more conventional high-risk clinicopathological characteristics of PTC
[77]. Among the various clinicopathological risk factors, extrathyroidal invasion, lymph node
metastasis, and advanced clinicopathological stages III and IV most reliably predict thyroid
cancer progression, recurrence, aggressiveness, and ultimately, higher morbidity and mortal‐
ity [78]. Interestingly, among the various clinicopathological characteristics of PTC, many
studies have found that BRAF mutation is also most commonly associated with these three
risk predictors. This suggests that BRAF mutation may play a role in promoting the progression
of PTC to ATC. Thus, BRAF mutation is a driving force behind the aggressive pathological
characteristics of PTC and predicts a poorer prognosis for patients with PTC
5.2.4.2.2. Association of BRAF mutation with recurrence of PTC and loss of radioiodine avidity in
recurrent tumors
Many studies have investigated the predictive value of the BRAF mutation for PTC recurrence
and have shown the association of BRAF mutation in the primary PTC with loss of radioiodine
avidity in the recurrent tumors [79].
5.2.4.2.3. Molecular bases for BRAF mutation-promoted invasiveness and progression of PTC
The oncogenic strength of BRAF mutation and the molecular events coupled to them in the
cell cause genetic instability [80]. BRAF mutation has a close association with aberrant
methylation of several important tumor suppressor genes in PTC including tissue inhibitor of
matrix metalloproteinase-3 (TIMP3), death-associated protein kinase (DAPK), SLC5A8, and
retinoic acid receptor 2 (RAR2) [81] which can further promote invasiveness and progression
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of PTC. Interestingly, a recent study demonstrated overexpression of VEGF in association with
BRAF mutation in PTC [82]. Therefore, adding to the mutation-induced progression and
invasiveness of PTC, the authors also showed that BRAF V600E promoted activation of the
nuclear transcription factor NF kappaB-coupled signaling, which in turn promoted matrigel
invasion of thyroid cancer cells. The efficacy of radioiodine treatment for thyroid cancer
depends on the integrity of the iodide-metabolizing system of the thyroid cell [83]. Interest‐
ingly, BRAF mutation was found to be associated with decreased expression of thyroperoxi‐
dase (TPO) [84], Na+/I− symporter (NIS) [85], Tg [86], and pendrin [87] in primary or recurrent
PTC tumors. Conditional expression of BRAF V600E in rat thyroid cell lines led to silencing of
all these thyroid-specific iodide metabolizing genes [88]. Methylation was shown to be a
mechanism mediating the silencing of some of these thyroid genes.
5.2.4.2.4. Testing of BRAF mutation as new dimension to risk stratification and clinical management
of PTC
BRAF mutation may represent a novel and useful prognostic molecular marker for PTC. Like
several conventional clinicopathological factors, particularly extrathyroidal invasion, lymph
node metastasis, and diseases stages III and IV. BRAF mutation similarly has a high predictive
value for PTC recurrence [85]. This novel prognostic factor may assist in deciding how
aggressive the initial treatment of the patient should be and in deciding how vigilantly and
aggressively patients should be managed after the initial treatment. PTC patients with BRAF
mutation may need to be more closely monitored by a more liberal battery of diagnostic tests,
such as more aggressive use of imaging methods.
5.2.5. P53 inactivation
P53 is known as “policeman of the genome” [89]. Alterations in the P53 tumor suppressor gene
by inactivating point mutations, usually involving exons 5–8, or by deletion result in progres‐
sive genome destabilization, additional mutations, and propagation of malignant clones.
Among thyroid tumors, P53 mutations are generally restricted to poorly differentiated thyroid
cancer (PDTC) and ATC. Point mutations of P53 occur in approximately 60% of ATC and in
25% of PDTC [90]. Because of their high incidence in undifferentiated thyroid cancer, the
presence of P53 mutations may be predictive of a highly aggressive thyroid cancer.
5.3. DNA mutation panels
Mutations of the RET/RAS/BRAF/MAPK pathway gladiators are responsible for more than 70%
of PTCs and 80% of FTCs, but the sensitivity and specificity of these mutations are too low to
be clinically relevant. But, because almost 70–80% of thyroid cancers should have at least one
of these mutations, a panel of all the mutations may be able to improve the diagnostic accuracy
of thyroid tumor FNA cytology. Signatures from gene expression profiles will eventually be
used to construct new DNA mutation panels for FNA-based diagnosis of thyroid nodules [91].
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5.4. Epigenetic biomarkers
Currently, epigenetic refers to the study of heritable changes in gene expression that occurs
without any alteration in the primary DNA sequence [92]. Epigenetic information that fulfills
the requirement of heritability can be classified into three distinct types: DNA methylation,
histone modifications, and noncoding RNAs. In thyroid cancer, DNA methylation, histone
modifications, and microRNA silencing have all been studied, but there is minimal data on
nucleosome positioning.
Aberrant methylation, or hypermethylation, of tumor suppressor genes has been identified in
many human tumors including thyroid tumors [93]. Hypermethylation of multiple genes has
been identified in association with the PIK3/AKT pathway in FTC and of the MAPK pathway
in PTC. Hypermethylation has also been identified in benign thyroid tumors, though to a lesser
extent than in thyroid carcinomas. A close association between BRAF mutation and aberrant
methylation of several tumor-suppressor genes in PTC has been reported [81]. Aberrant
methylation also involves thyroid-specific genes such as the NIS, the promoter of the TSH
receptor, the genes for the putative thyroid follicular cell apical iodide transport (pendrin and
SCL5A8) [93]. Suppression of these thyroid iodide-metabolizing molecules results in the loss
of cancer cells ability to concentrate iodine, rendering tumors insensitive to radioiodine
therapy.
5.4.1. TSHR function and signaling
TSH is the main regulator of thyroid gland growth and development. Binding of TSH to TSHR
stimulates thyroid epithelial cell proliferation and regulates the expression of differentiation
markers such as Tg, TPO, and the NIS, necessary for the synthesis of thyroid hormones. Two
G protein-dependent pathways are activated by TSHR: (i) Gαs-adenylate-cAMP activates
protein kinase A (PKA)—phosphorylates the transcription factor CREB, thereby increasing its
transcriptional activity and (ii) Gαq-phospholipase C–releasing inositoltriphosphate (IP3) and
diacylglycerol (DAG)—activates protein kinase C, which promotes proliferation via the RAF/
MEK/ERK pathway. Complex cross-talk occurs between these pathways and other signaling
pathways including the PI3/Akt, PKC/NFkB, and JAK/STAT pathways [94, 95].
5.4.2. TSHR alterations related to thyroid cancer
Excesses or defaults in TSHR activity may play a role in thyroid disease and cancer. Both can
be achieved by a number of mechanisms including mutations in critical domains, improper
epigenetic marking of the gene, or incorrect transcriptional regulation.
5.4.3. Altered levels of TSHR expression
Quantitative analysis of promoter hypermethylation in thyroid cancer has involved RASSF1A,
TSHR, RARβ2, DAPK, S100, p16, CDH1, CALCA, TIMP3, TGF-β, and GSTpi [81]. The TSHR
gene promoter is frequently hypermethylated in thyroid carcinoma, with preferential meth‐
ylation in undifferentiated carcinoma. In contrast, TSHR gene promoter is unmethylated in
the normal thyroid and in benign tumors (thyroid adenoma). TSHR stimulates several key
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steps in thyrocyte concentration of iodine, including uptake by NIS and oxidation before
incorporation into Tg by thyroid peroxidase [96]. Promoter hypermethylation resulting in
decreased expression of TSHR and NIS may result in a decreased ability to concentrate iodine,
rendering ablative doses of 131I ineffective. Promoter hypermethylation of TSHR is reported
in 34–59% of patients with PTC [97]. NIS expression and iodide uptake requires functional
TSHR. Low or absent TSHR expression correlates with worse prognosis in thyroid carcinomas
[98].
5.4.4. BRAF mutational status and silencing of TSHR gene
It is thought that the loss of responsiveness to 131I is because of the loss of function of iodine-
metabolizing proteins, such as NIS and TSHR. Tumor cells harboring BRAF V600E mutation
have decreased NIS and TSHR gene expression compared with similar cells without the
mutation. Several recent in vitro and in vivo mouse studies have demonstrated that BRAF
inhibition with small-molecule MAPK pathway inhibitors restores the expression of iodine-
metabolizing proteins and increases susceptibility to radioiodine ablation [99]. BRAF muta‐
tions are associated with decreased expression of mRNAs for the NIS and the TSH receptors
that are considered markers of thyroid differentiation [100] (Figure 5).
The molecular mechanism involved in this V600E BRAF-induced silencing of thyroid genes is
also unclear. Liu et al. showed the restorability of the expression of several key thyroid iodide-
metabolizing genes by suppressing BRAF/MEK/MAP kinase pathway in thyroid cells ex‐
pressing the V600E BRAF mutant. Using TSHR gene as a model, they showed that the effect
Figure 5. Classical TSHR signaling pathway and the framing network in thyrocyte proliferation. The bold arrows rep‐
resent the classical TSHR signaling pathway towards proliferation. Normal arrows integrate cross talking molecules
from other signaling pathways. Dashed lines represent other targets that may or may not be related to this pathway.
Commonly altered molecules in thyroid cancer that may alter the integrity of the signaling network are enclosed in a
square. Examples of integration between the classical TSHR/PKA and the MAPK/ERK, PI3K/Akt and Wnt/β-catenin
pathways are provided.
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of the BRAF/MEK/MAP kinase pathway on thyroid gene expression occurred through
alteration of gene promoter activity, which may involve methylation [101].
5.5. Genomics
It includes the mapping and sequencing of the genome, as well as the analysis of the infor‐
mation gained from mapping and sequencing in the context of their biological significance and
biomedical application. cDNA microarrays, oligonucleotide arrays, and serial analysis of gene
expression (SAGE) are the various gene expression profiling technologies currently in use
[102] which allow the study and comparison of the expression of thousands of genes simul‐
taneously in varying conditions and will someday lead to the development of DNA signatures
unique to each patient leading to patient specific treatment. In 2001, the first gene expression
profile in thyroid cancer was done [103].
5.6. Proteomics
Proteomics is defined as the study of protein structure and function. The term was first
introduced as an analogy to “genomics”, but in this case referring to the entire protein spectrum
[104]. Several immunohistochemical markers representing different components of the cell,
such as the membrane, the cytoplasm, or the nucleus, have been studied in thyroid neoplasms
[105]. The proteomic information also takes into account post-translational changes that are
not detected at the mRNA level, as well as protein expression. The advantage of proteomics
is the ability to detect biomarkers leaked into circulation from the patient’s serum or plasma.
Proteomics combines multidimensional separation systems based on mass spectrometry
analysis and protein chip technology to detect complex mixture of proteins and peptides from
either tissue or serum with high sensitivity and specificity [106]. The first study that established
a proteomic profile of benign and malignant human thyroid tissue was reported in 2002 [107].
5.6.1. BRAF protein overexpression in thyroid cancer
The BRAF copy number gain, which results from either numerical changes of chromosome 7
or gene amplification, occurs in a significant portion of benign and malignant follicular thyroid
tumors, including those of conventional and oncocytic types. This abnormality is associated
with overexpression of BRAF protein and did not coincide with the presence of other mutations
leading to activation of the MAPK pathway, suggesting that BRAF copy number gain may
represent another mechanism of BRAF activation in thyroid tumors. It has been known for a
long time that clonal numerical changes of chromosome 7 are common in benign and malig‐
nant thyroid tumors, and most of them are chromosome gains, particularly trisomy 7 [108].
Although gains of chromosome 7 lead to the increase in copy number of many genes located
on this chromosome, data suggest that BRAF may represent an important target for the
selection and clonal progression. The numerical changes of BRAF include gains of one to three
extra copies of the gene and result in the modest overexpression (near to double) of the protein.
This increased protein expression leads to additional stimulation of the MAPK pathway,
although significantly lower as compared to more than 400-fold increase of BRAF kinase
activity imposed by V600E point mutation [109]. A study by Kondo et al. revealed focal
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expression of wild-type BRAF in nonneoplastic thyroids and diffuse expression in benign
adenomas and well-differentiated carcinomas regardless of their BRAF gene mutational status.
Increased expression of wild-type BRAF may play important roles in the proliferation of
transformed follicular cells [1].
6. Molecular analysis of BRAF and RAS genes
The study was aimed and designed to analyze the mutations, if any, in the coding exons (1
and 2) of RAS gene family (NRAS, HRAS and KRAS) and exon 15 of BRAF gene along with the
analysis of BRAF protein expression and to establish the correlation of RAS and BRAF gene
mutation and BRAF expression with clinicopathological variables of thyroid cancer patients.
A total of 60 consecutive thyroid tumors and their adjacent normal tissues surgically resected
either by total thyroidectomy/hemi-thyroidectomy or lobectomy over a period of 3 years were
included in the study for sequence analysis of RAS gene family (HRAS, NRAS, and KRAS) and
BRAF gene. By histopathological conformation, all the resected samples were established as
thyroid cancer. Majority of the patients had attended the hospital with a clinical presentation
of a lump or nodule. In this study, 80% (48 of 60) of cases were females and 20% (12 of 60) were
males with a male: female ratio of 1:4. The cases in the age group of <45 were 60% (36 of 60)
and exceeded than ≥45 years which were 40% (24 of 60). Only 10% (6 of 60) of patients were
smokers who were all males and 90% (46 of 60) were nonsmokers. Benign thyroid diseases
were found in 80% (48 of 60) patients. Tumor samples were histologically confirmed as
differentiated thyroid carcinomas [PTC—70% (42 of 60) and FTC—13.4% (8 of 60), respectively]
except few cases of MTC—6.6% (04 of 60) and Hürthle cell cancer—10% (6 of 60). Well-
differentiated cancer grade was present in 95% (57 of 60) thyroid cancer patients. The clini‐
coepidemiological and pathological characteristics of these patients are listed in Table 3.
DNA isolated from the samples (tumor tissues and corresponding normal tissues) (Figure 6)
was subjected to PCR to amplify the hot spot coding exon 15 of BRAF gene. Besides these,
six other coding exons of RAS family of genes were amplified (1 and 2 exons of HRAS,
NRAS and KRAS). The representative pictures of each exon of both the genes are given in
Figure 7. After PCR amplification, the PCR products were subjected to DNA sequence anal‐
ysis.
To identify the sequence variations, the electrophoregram obtained after sequencing of the
PCR products was compared manually with the reference sequence of the BRAF and RAS
genes deposited in the NCBI gene bank database. In addition, the electrophoregrams of both
the genes were compared with the corresponding reference sequence of BRAF and RAS
gene by aligning in “Cluster X software” to find somatic aberrations like insertions, dele‐
tions, or substitutions.
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TSH = Thyroid-stimulating hormone, n = Number.
Table 3. Clinicoepidemiological and clinicopathological variables of thyroid cancer patients used for mutational
analysis in our center (SKIMS, India).
Figure 6. 1% Agarose gel electrophoresis of DNA isolated from blood, tumor tissue, and adjacent normal tissue of thy‐
roid cancer patient. Lane M consists of lambda DNA-EcoRI digest. Lanes 1–3: DNA derived from thyroid tumor tissue.
Lane 4: DNA derived from adjacent normal tissue. Lane 5: DNA derived from blood of thyroid cancer patient.
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Figure 7. PCR amplification of different exons of BRAF and RAS genes. Lane M: molecular size marker 100 bp. Lanes
1–5, 6 and 7: amplified product from DNA of patient samples.
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6.1. Mutational spectrum of BRAF gene
Total mutations of BRAF in this study were found to be 25% (15 of 60). All of them were
transversions (T > A) at nucleotide position 1799 in exon 15. This mutation affects codon 600
of BRAF gene. This V600E mutation was further confirmed by reverse sequence of the same
samples (Figures 8 and 9). The matched constitutional DNA contained the wild-type sequence
in every case, demonstrating the somatic nature of these mutations in thyroid cancer.
Figure 8. Partial electropherograms (forward) of the adjacent normal (left) and mutants (right) in exon 15 of the BRAF
gene codon 600 (TGA→CGA).
Figure 9. Partial electropherograms (reverse) of the adjacent normal (left) and mutants (right) in exon 15 of the BRAF
gene codon 600 (TGA→CGA).
Among 25% (15/60) mutations of BRAF gene found in this study, 40% (10 of 25) of cases hav‐
ing elevated TSH levels were harboring mutation compared to 14.2% (05 of 35) cases having
normal TSH levels and this difference showed a strong statistical significance (P < 0.05) (Ta‐
ble 4). Among the various histological types of thyroid cancer, mutations were restricted on‐
ly to PTC. So, 35.7% (15 of 42) of PTC patients were having mutation in codon 600 of BRAF
gene compared to follicular and other types of thyroid cancer which did not contain any
mutation and this difference in mutation frequency between different histological types of
tumors was statistically significant (P < 0.05). All the mutations were found in well-differen‐
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tiated thyroid carcinomas (26.3% – 15 of 57) when compared to poorly differentiated thyroid
carcinomas (P < 0.05). In thyroid cancer patients having <45 years of age, 23.5% (8 of 34) of
patients with stage I disease had mutation compared to 100% (02 of 02) in stage II patients.
Similarly, thyroid cancer patients having ≥45 years of age, 33.3% (05 of 15) of patients with
stage I disease have mutation compared to stage II patients who were free from mutation (P
< 0.05). In this study, 34.6% (9 of 26) patients having vascular and capsular invasion were
having mutation compared to only 17.6% (06 of 34) of mutation positive patients free from
invasion (P < 0.05). No significant association of this mutation was found in this report with
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TSH = Thyroid-stimulating hormone, n = number.
Table 4. Clinicoepidemiological and clinicopathological variables of thyroid cancer patients versus the mutant
phenotypes of the BRAF gene.
The substitution of the negatively charged glutamic acid for an uncharged valine at position
600 may mimic the normal physiological phosphorylation of T599 and S602 resulting in a
constitutively activated BRAF kinase [71] and stimulating BRAF activity up to 700-fold [111].
Studies along with an updated meta-analysis continue to show a strong relationship of BRAF
mutation with aggressive clinicopathological characteristics of PTC [112, 113]. In conclusion,
our study shows that the BRAF mutations characterize the aggressive pathway of thyroid
tumorigenesis.
6.2. Mutational spectrum of RAS genes
Exons 1 and 2 each of NRAS, HRAS, and KRAS genes were screened for mutations in 60 tissue
samples of thyroid cancer cases. Total six exons of RAS gene family were screened for
mutations especially in codons 12, 13, and 61. No mutations were observed in any of the six
exons studied, particularly in codons 12, 13, and 61 (Figure 10). Studies on a variety of tumors
have demonstrated some “hot spots” in RAS gene family that are susceptible to point muta‐
tions. Many studies have detected different types of RAS mutations in human thyroid tumors
[114, 115], but RAS gene family members have not been screened for mutation in the same
sample series in thyroid tumors in Kashmiri patients. Activating RAS mutations have been
reported to occur in ∼30% of human cancers [116]. Our study was limited to screening of two
hot spot exons of each RAS family of genes but in contrast to most of the studies showed no
activating mutations in the thyroid tumors [117, 118]. Furthermore, many studies have
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reported mutual exclusiveness of BRAF, RAS as well as RET/PTC rearrangements in papillary
thyroid cancers [1, 119]. As PTC is more prevalent in our region BRAF mutations predominate;
hence, RAS mutations were not found in our study due to their mutual exclusiveness. In
conclusion, it is evident from our study that although thyroid cancer is highly prevalent in this
region, the mutational events for RAS genes do not seem to be involved in the thyroid
carcinogenesis.
6.3. Polymorphic study of HRAS T81C SNP
DNA sequencing of HRAS exon 1 showed frequent T to C substitution in codon 27 of exon 1
at cDNA position 81, which is located in a wobble base position (Figure 11). The substitution
Figure 10. Partial electropherograms (forward) of exons 1 and 2 of the NRAS, HRAS, and KRAS genes.
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(T81C) in codon 27 was found in 16 of 60 (26.6%) tumor tissue samples. HRAS 81 T > C
substitution was found in 12 of 42 (28.5%) PTC tissues and 04 of 08 (50%) FTC tissues. HRAS
T81C was frequently observed and was considered to be an informative SNP. Since this
polymorphism has been reported only once in thyroid cancer; further, evaluation was
imperative, to elucidate the conformity of the results in the backdrop of different ethnic
backgrounds; thus, we conducted a case-control polymorphic study of HRAS T81C to assess
the role of this SNP in thyroid cancer in Kashmiri population (North India). A total of 140
peripheral blood samples from confirmed thyroid cancer patients were collected from the
department of Nuclear Medicine, SKIMS over a period of two years. Also 170 blood samples
were collected from control subjects who were not having any sort of malignancy from the
same hospital and belonging to the same geographical area, ethnic background for polymor‐
phic analysis of HRAS T81C SNP. The cases included 19% (26 of 140) males and 81% (114 of
140) female patients (1:4.4), and the controls consisted of 82.4% (140 of 170) males and 17.6%
(30 of 170) females. Of the total number of cases, 89% (124 of 140) were nonsmokers and 11%
(16 of 140) were smokers. The subjects were considered nonsmokers only if until the day of
sample collection they had not consumed tobacco and subjects were considered smokers if
they are smoking presently or had quit smoking since last 6 months or less before sample
collection. Only 29% (40 of 140) patients were above 45 years of age, and 71% (100 of 140)
patients were below 45 years of age. Table 5 shows demographic information and other
parameter of cases and controls. The representative pictures of the amplicons and the RFLP
are shown in Figure 12. The distribution of HRAS T81C allele frequency, its genotypes in cases
and controls are shown in Tables 6 and 7. Due to the very low frequency of the ‘CC’ genotype
and an increased risk associated with TC and CC genotypes, TC + CC was compared against
TT. Frequencies of TT, TC, and CC genotypes among cases were 41.4%, 38.6%, and 20%, while
in controls 84.1%, 11.7%, and 4.2%, respectively, with odds ratio (OR) of 7.4; 95% confidence
interval (CI) = 4.3–12.7. The cases had a higher frequency of the rare allele (TC + CC) (58.6%)
than the controls (15.9%), and this pattern of distribution of rare alleles among two groups
Figure 11. Partial electropherograms (forward) of the adjacent normal (left) and mutants (right) in exon 1 of the HRAS
gene codon 27 (CAT→CAC).
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showed statistical significance (P < 0.05). This finding shows an increased risk with TC + CC
combination of genotypes against TT genotype. The frequency of mutant C allele was 39.3%
in cases and 10% in controls. This observation showed a highly statistical significance of rare
allele (C) between cases and controls (P < 0.05) with an O.R (95% C.I) of 5.8 (3.7–8.7). When
classified further into groups, our study interestingly found higher percentage of rare allele
(TC + CC) in FTC (82%, 18 of 22) compared to PTC (54%, 64 of 118) (P < 0.05). Association of
variant allele with other clinicopathological characteristics is given in Table 7. While age,
dwelling, gender, smoking status, and genotype (TC + CC) were associated with thyroid cancer
in odds adjusted univariate analysis, the same parameters were associated with this disease
in multivariate logistic regression analysis [120].
Characteristics Cases
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Characteristics Cases
n = 140 (%)
Controls
n = 170 (%)
χ2-Value P-Value
Stage, ≥45 years
Stages I and II













TSH = thyroid-stimulating hormone, WD = well-differentiated thyroid cancer, PD = poorly differentiated thyroid cancer.
Table 5. Frequency distribution analysis of selected demographic and risk factors in thyroid cancer cases and controls
taken for HRAS T81C polymorphic study.
Figure 12. (A) PCR-amplified product of HRAS exon 1 (186 bp). (B): fragment digestion of PCR product by DraIII. TT
allele (186 bp) shown in lanes 1 and 6; the TC heterozygous (186 bp, 128 bp and 58 bp) in lane 4; and homozygous CC
variant (128 bp and 58 bp) in well 2, 3, 5, 7–9; M = 100 bp ladder.
Cases
n = 140 (%)
Controls
n = 170 (%)























Table 6. Distribution of HRAS T81C genotypes and its allele frequency in cases and controls.
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TSH = thyroid-stimulating hormone, WD = well-differentiated thyroid cancer, PD = poorly differentiated thyroid cancer.
Table 7. Association between HRAS T81C phenotypes and clinicopathologic characteristics of thyroid cancer patients.
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In thyroid cases, however, we found higher frequency of variant genotypes as compared to
other studies conducted on various cancers [121]. Our study revealed a sevenfold increased
risk of thyroid cancer in carriers of the variant genotype (TC + CC) in cases. Therefore, our
report reveals a significant risk for thyroid cancer, both either when stratified with C allele or
in combination of the variant genotypes TC + CC compared with the TT genotype. Consistent
with the tissue specificity hypothesis and various studies that had confirmed that the HRAS
gene plays a more important role in bladder cancer acquired amino acid mutations in the
hotspot codons 12, 13, and 61, which prolong the GTP-bound activated state of the HRAS
product [122]. This polymorphism does not lead to the alteration of RAS protein structure, and
it affects the cancer susceptibility possibly through linkage disequilibrium with other potential
functional variants of HRAS. One of the linkage candidates is a region of variable tandem
repeats about 1 kb downstream exon 4, with a possible transcriptional enhancer activity [123].
Another associated polymorphic site is hexanucleotide repeat located about 80 bp upstream
of the 5′-end of exon 1 [124]. Yet another report has shown that HRAS T81C might be serving
as a marker of other polymorphisms in intron D2 of HRAS that would act as regulators of IDX
inclusion [125]. In conclusion, HRAS T81C SNP has been found to moderately increase thyroid
cancer risk with variant alleles implicated more in follicular thyroid tumors.
6.4. Analysis of protein expression of BRAF
In this part of study, a total of 60 previously analyzed TC and their adjacent normal tissues
were further analyzed for BRAF protein expression. Table 3 depicts the clinicopathological
characteristics of the studied subjects. Figure 13 shows the representative picture of the
extracted proteins run on SDS PAGE. Out of 60 cases of thyroid cancer, 90% (54 of 60) showed
overexpression of BRAF protein (Figure 14) and the rest 10% (6 of 60) of the cases showed
normal protein (BRAF) expression. Overexpression of BRAF protein in males was observed to
be 84% (10 of 12) and in females as 91.6% (44 of 48). Among nonsmokers 96.3% (52 of 54) showed
overexpression compared to smokers who showed only 33.4% (2 of 6) overexpression in BRAF
protein and the difference is statistically significant (P > 0.05). BRAF protein overexpression
was found to be in 97.7% (41 of 42) of PTC, 75% (6 of 8) of FTC, and 70% (07 of 10) of medullary/
Figure 13. Representative gel picture of 10% SDS-PAGE. In each case 24 μl sample (20μl of the crude protein extract + 4
μl sample buffer) from tumor tissue and adjacent normal was loaded.
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Hürthle cell carcinomas with a statistically significant association (P > 0.05). When we com‐
pared BRAF gene mutational status with BRAF protein expression, 86.7% (13 of 15) of BRAF
mutation positive patients were having overexpression of BRAF protein, whereas 91.2% (41
of 45) of patients having wild-type BRAF status were having overexpressed BRAF protein (P
> 0.05). No significant association of BRAF overexpression with any other clinicopathological
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Nonsmoker 54 (90%) 02 (3.7%) 52 (96.3%) Reference <0.05
Figure 14. Western blot analysis of BRAF protein in thyroid tumor and adjacent normal tissues. Representative immu‐
noblot showing the expression of BRAF protein in thyroid tumor tissue as compared to their adjacent normals. Extracts
from samples were separately run for β-actin protein expression as loading control. Lanes T: protein extracted from
tumor tissue. Lanes N: protein extracted from normal tissues. Membrane was probed with a polyclonal antibody spe‐
cific for BRAF protein.
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TSH = Thyroid-stimulating hormone, WD = well-differentiated thyroid cancer, PD = poorly differentiated thyroid cancer.
Table 8. Association of clinicopathological and clinicoepidemiological characteristic with BRAF protein
overexpression.
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As an important positive regulator of the MAP kinase signaling pathway, BRAF protein forms
a multiprotein complex with MEK (downstream regulatory molecule), hence keeping MAP
kinase pathways always on. Therefore, by positive regulation of the MAP kinase signaling
pathway, BRAF can accelerate the proliferation of tumor cells. As we could not identify a
distinct association between BRAF expression and BRAF mutation in thyroid tumors in
accordance with other studies, possibly there might be another potential mechanism of BRAF
activation other than mutational events. BRAF copy number gain in thyroid tumors has
recently been studied by fluorescence in situ hybridization (FISH) where trisomy, tetrasomy
for chromosome 7 was the most common alteration in tumors [108]. Although gains of
chromosome 7 lead to the increase in copy number of many genes located on this chromosome,
our data suggest that BRAF gene may represent an important target for the selection and clonal
progression. Furthermore, BRAF copy number is directly proportional to amount of BRAF
protein [1]. Therefore, it is tempting to speculate that weak stimulation of the MAPK pathway
may participate in thyroid carcinogenesis.
7. Analysis of promoter methylation of TSHR gene
This study was aimed and designed to analyze the promoter hypermethylation of TSHR gene
by methylation-specific PCR (MS-PCR) and to correlate it with clinicopathological character‐
istics of thyroid cancer patients and BRAF mutation. For this study, sixty (60) thyroid cancer
tissues and their corresponding normal tissues were analyzed. The clinicopathological
characteristics of the studied subjects are given in Table 3. In case when promoter region was
highly methylated (both alleles) only the methylated band was detected and when promoter
was partially methylated both methylated and unmethylated bands were detected. The
representative picture of promoter hypermethylation of TSHR gene by methylation-specific
PCR (MSP) is given in Figure 15.
Figure 15. Representative picture of promoter hypermethylation of TSHR gene by MSP (4% agarose). L: 50 bp DNA
marker. U (91 bp) indicates presence of unmethylated TSHR. M (88 bp) indicates presence of methylated TSHR. P and
N indicate positive and negative controls, respectively. Distilled water was used as negative control in place of DNA.
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Variable Cases
n = 60 (%)
TSHR methylation
(n = 60)
OR (95% CI) P-Value
Positive
n = 15 (25%)
Negative
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TSH = thyroid-stimulating hormone, WD, PD = well and poorly differentiated thyroid cancer.
Table 9. Association of TSHR promoter methylation with different variables of thyroid cancer patients.
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The promoter region of TSHR gene was found to be methylated in 25% (15 of 60) of the thyroid
cancer patients studied. The promoter methylation was found to be 27.7% (10 of 36) in patients
<45 years of age compared to 20.8% (5 of 24) in patients ≥45 years of age. When methylation
was compared with smoking status of patients, 33.3% (2 of 6) of smokers had methylated
promoter region than 24% (13 of 54) of nonsmokers but the association was statistically
insignificant (P > 0.05). When patients were grouped according to histological types, 28.5% (12
of 42) of PTC patients and 25% (2 of 8) of FTC patients had methylated promoter region, also
10% (01 of 10) of patients having other types of thyroid cancers were having methylation in
promoter region (P > 0.05). Patients having elevated TSH levels showed strong association
with methylation (OR = 4.0, P = 0.02) than patients having normal TSH levels. Association of
TSHR promoter methylation with other clinicopathological characteristics is given in Table
9 [126].
TSHR stimulates thyroid epithelial cell proliferation and several key steps in thyrocyte
concentration of iodine, including uptake by NIS and oxidation before incorporation into Tg
by thyroid peroxidase. Excesses or defaults in TSHR activity may play a role in thyroid disease
and cancer. Aberrant methylation of the TSHR gene leads to loss of TSHR gene expression [96].
Promoter hypermethylation resulting in decreased expression of TSHR and NIS may result in
a decreased ability to concentrate iodine, rendering ablative doses of 131I ineffective [97]. To
summarize, our results showed a higher frequency of TSHR gene methylation in thyroid
tumors and demonstrated it as a molecular pathway underlying the silencing of this gene.
Moreover, the ability to achieve restoration of gene expression by nonnucleoside
demethylating agents (such as procainamide) and nucleoside-analogue demethylating agents
(such as azacitidine and decitabine) [96] suggests that DNA demethylating agents could be
used to improve the efficiency of TSH promoted radioiodine therapy in epithelial thyroid
cancers, particularly in those that have lost the response to TSH manipulation.
7.1. Association of TSHR promoter methylation with BRAF mutation spectrum
Now that we found BRAF and TSHR gene hypermethylation are highly implicated in thyroid
tumors, we explored their association in the same group of patients. For this part of study, 60
thyroid cancer tissues and their corresponding normal tissues were analyzed. These were the
same patients, wherein mutational analysis of BRAF gene and hyper methylation of TSHR was
carried out. Here, we compared the BRAF mutations with TSHR promoter methylation. Out
of 60 patients, TSHR methylation was found in 25% (15 of 60) patients and BRAF was found
in 25% (15 of 60) patients. Out of 15 patients wherein mutations of BRAF gene were found,
TSHR promoter was methylated in 73.3% (11 of 15) patients (Table 10). The presence of
methylation in TSHR gene was found to be significantly associated with the BRAF mutation
positive status (P < 0.05). Similarly, out of 45 patients, wherein mutations of BRAF gene were
absent, TSHR promoter was methylated in only 8.8% (4 of 45) patients and rest of 91.2% (41 of
45) patients showed absence of TSHR promoter methylation (Table 10). Among the thyroid
cancer patients studied, TSHR promoter methylation was significantly greater in patients with
BRAF mutated (73.3%) than those with wild-type BRAF (8.8%) [126].
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Present 15 11(73.3%) 04(26.7%) 0.005
Absent 45 04(8.8%) 41(91.2%)
Table 10. Association of BRAF mutation with TSHR promoter methylation.
Several recent in vitro and in vivo mouse studies have demonstrated that BRAF inhibition with
small-molecule MAPK pathway inhibitors restores the expression of iodine-metabolizing
proteins and increases susceptibility to radioactive iodine (RAI) [99, 127]. Our finding is an
addition to the link of promoter methylation of TSHR gene with V600E BRAF and also
represents an interesting further step from previous studies showing promoter methylation
as a mechanism in silencing of this gene in thyroid cancer [96]. Our results also conclude that
TSHR methylation is significantly associated with BRAF mutation spectrum. These diagnostic
and therapeutic implications of TSHR gene methylation and its link with BRAF mutation in
thyroid tumor clearly deserve further clinical investigation in other ethnic populations as well
as our population of Kashmir and because of very few studies done, our results need to be
further verified in larger cohort of patients to confirm the link between BRAF mutations and
TSHR promoter methylation.
8. Conclusion
In conclusion, thyroid tumors represent an appropriate model for the study of epithelial
neoplastic transformation. Thyroid cancers accumulate a number of alterations at the genomic
level, and it has been proposed that genomic instability has a crucial role in the progression of
thyroid neoplasms. Recent advances have improved our understanding of its pathogenesis;
these include the identification of genetic alterations in RET, RAS, and BRAF that activate a
common effector pathway involving the MAP kinase signaling cascade. Several thyroid-
specific protein molecules play a key role in iodide-metabolizing process, including thyroid-
stimulating hormone receptor (TSHR), sodium iodide symporter (NIS), Tg, TPO, and the
thyroid gene transcription factors TTF-1 and Pax-8. Loss of expression of the genes for these
molecules is common in aggressive thyroid cancer and is a sufficient cause for the loss of
radioiodine avidity and failure of radioiodine therapy in this cancer.
Although TC is one of the least deadly forms of cancer, research in the field has remained on
the cutting edge of science and technology, but better diagnostic tests and predictors of tumor
aggressiveness are necessary. Nowadays, novel treatments are being designed based on our
enhanced understanding of this disease process. The use of sophisticated genetic tools is
generating a wealth of information for the better management of patients with TC.
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Our study shows that the BRAF mutations as well its protein overexpression characterize the
aggressive pathway of thyroid tumorigenesis. The high implication of this gene can thus be
exploited for diagnosis and follow-up of thyroid cancer patients. On the other hand, RAS genes
do not seem to be involved in the thyroid carcinogenesis in our series of patients with thyroid
tumors with an exception of a germ line alteration in HRAS T81C SNP that moderately increase
thyroid cancer risk. Moreover, the ability to achieve restoration of gene expression of thyroid
iodide metabolizing genes by demethylating agents (such as azacitidine and decitabine)
suggests that DNA demethylating agents could be used to improve the efficiency of radioio‐
dine therapy in epithelial thyroid cancers. We found higher frequency of TSHR gene methyl‐
ation in thyroid tumors, an event underlying the silencing of this gene supporting the above
hypothesis about the role of TSHR hypermethylation in aggressive thyroid tumors. BRAF
mutation is associated with silencing of various thyroid iodide-metabolizing genes including
TSHR and loss of radioiodine avidity, and this is supported by our results that conclude with
TSHR methylation being significantly associated with BRAF mutation spectrum. These
diagnostic and therapeutic implications of TSHR gene methylation and its link with BRAF
mutation in thyroid tumor clearly deserve further clinical investigation in other ethnic
populations as well as our population of Kashmir.
Because of very few studies done on thyroid cancer from this region and relatively lesser
sample size of our study the results need to be further verified in larger cohort of patients to
confirm the link between various molecular assaults and thyroid carcinogenesis.
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